tetano
Editor, Senior Moderator
ACS Chem Biol
. 2022 Jun 19.
doi: 10.1021/acschembio.2c00378. Online ahead of print.
Host Kinase CSNK2 is a Target for Inhibition of Pathogenic SARS-like β-Coronaviruses
Xuan Yang[SUP] 1 2 [/SUP], Rebekah J Dickmander[SUP] 2 3 4 5 [/SUP], Armin Bayati[SUP] 6 [/SUP], Sharon A Taft-Benz[SUP] 2 7 [/SUP], Jeffery L Smith[SUP] 1 [/SUP], Carrow I Wells[SUP] 1 [/SUP], Emily A Madden[SUP] 7 [/SUP], Jason W Brown[SUP] 8 [/SUP], Erik M Lenarcic[SUP] 2 3 4 [/SUP], Boyd L Yount Jr[SUP] 9 [/SUP], Edcon Chang[SUP] 8 [/SUP], Alison D Axtman[SUP] 1 2 [/SUP], Ralph S Baric[SUP] 2 9 [/SUP], Mark T Heise[SUP] 2 7 [/SUP], Peter S McPherson[SUP] 6 [/SUP], Nathaniel J Moorman[SUP] 2 3 4 [/SUP], Timothy M Willson[SUP] 1 2 [/SUP]
Affiliations
Abstract
Inhibition of the protein kinase CSNK2 with any of 30 specific and selective inhibitors representing different chemotypes, blocked replication of pathogenic human, bat, and murine β-coronaviruses. The potency of in-cell CSNK2A target engagement across the set of inhibitors correlated with antiviral activity and genetic knockdown confirmed the essential role of the CSNK2 holoenzyme in β-coronavirus replication. Spike protein endocytosis was blocked by CSNK2A inhibition, indicating that antiviral activity was due in part to a suppression of viral entry. CSNK2A inhibition may be a viable target for the development of anti-SARS-like β-coronavirus drugs.
. 2022 Jun 19.
doi: 10.1021/acschembio.2c00378. Online ahead of print.
Host Kinase CSNK2 is a Target for Inhibition of Pathogenic SARS-like β-Coronaviruses
Xuan Yang[SUP] 1 2 [/SUP], Rebekah J Dickmander[SUP] 2 3 4 5 [/SUP], Armin Bayati[SUP] 6 [/SUP], Sharon A Taft-Benz[SUP] 2 7 [/SUP], Jeffery L Smith[SUP] 1 [/SUP], Carrow I Wells[SUP] 1 [/SUP], Emily A Madden[SUP] 7 [/SUP], Jason W Brown[SUP] 8 [/SUP], Erik M Lenarcic[SUP] 2 3 4 [/SUP], Boyd L Yount Jr[SUP] 9 [/SUP], Edcon Chang[SUP] 8 [/SUP], Alison D Axtman[SUP] 1 2 [/SUP], Ralph S Baric[SUP] 2 9 [/SUP], Mark T Heise[SUP] 2 7 [/SUP], Peter S McPherson[SUP] 6 [/SUP], Nathaniel J Moorman[SUP] 2 3 4 [/SUP], Timothy M Willson[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35723434
- DOI: 10.1021/acschembio.2c00378
Abstract
Inhibition of the protein kinase CSNK2 with any of 30 specific and selective inhibitors representing different chemotypes, blocked replication of pathogenic human, bat, and murine β-coronaviruses. The potency of in-cell CSNK2A target engagement across the set of inhibitors correlated with antiviral activity and genetic knockdown confirmed the essential role of the CSNK2 holoenzyme in β-coronavirus replication. Spike protein endocytosis was blocked by CSNK2A inhibition, indicating that antiviral activity was due in part to a suppression of viral entry. CSNK2A inhibition may be a viable target for the development of anti-SARS-like β-coronavirus drugs.